{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:24:44Z","timestamp":1789457084137,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012431","name":"Celldex Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10637-020-00945-y","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T22:07:08Z","timestamp":1590790028000},"page":"1807-1814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley A.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-9504","authenticated-orcid":false,"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0083-4753","authenticated-orcid":false,"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0444-5870","authenticated-orcid":false,"given":"Saby","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1411-0417","authenticated-orcid":false,"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rogalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-4230","authenticated-orcid":false,"given":"Tibor","family":"Keler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"945_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm M-O, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"945_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang Y-H, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"945_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"945_CR4","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang S-Y, Melhem-Bertrandt A, Petrylak DP (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol 37:2592\u20132600. https:\/\/doi.org\/10.1200\/JCO.19.01140","journal-title":"J Clin Oncol"},{"key":"945_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237\u2013244. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00433.x","journal-title":"Kidney Int"},{"key":"945_CR6","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1093\/ndt\/gfp010","volume":"24","author":"JV Bonventre","year":"2009","unstructured":"Bonventre JV (2009) Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 24:3265\u20133268. https:\/\/doi.org\/10.1093\/ndt\/gfp010","journal-title":"Nephrol Dial Transplant"},{"key":"945_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semnephrol.2014.06.006","volume":"34","author":"K Berger","year":"2014","unstructured":"Berger K, Moeller MJ (2014) Mechanisms of epithelial repair and regeneration after acute kidney injury. Semin Nephrol 34:394\u2013403. https:\/\/doi.org\/10.1016\/j.semnephrol.2014.06.006","journal-title":"Semin Nephrol"},{"key":"945_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1681\/ASN.2004070530","volume":"16","author":"WK Han","year":"2005","unstructured":"Han WK, Alinani A, Wu C-L, Michaelson D, Loda M, McGovern FJ, Thadhani R, Bonventre JV (2005) Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 16:1126\u20131134. https:\/\/doi.org\/10.1681\/ASN.2004070530","journal-title":"J Am Soc Nephrol"},{"key":"945_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.pas.0000213353.95508.67","volume":"31","author":"F Lin","year":"2007","unstructured":"Lin F, Zhang PL, Yang XJ, Shi J, Blasick T, Han WK, Wang HL, Shen SS, Teh BT, Bonventre JV (2007) Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 31:371\u2013381. https:\/\/doi.org\/10.1097\/01.pas.0000213353.95508.67","journal-title":"Am J Surg Pathol"},{"key":"945_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1124\/pr.114.009373","volume":"68","author":"P Polakis","year":"2016","unstructured":"Polakis P (2016) Antibody drug conjugates for cancer therapy. Pharmacol Rev 68:3\u201319. https:\/\/doi.org\/10.1124\/pr.114.009373","journal-title":"Pharmacol Rev"},{"key":"945_CR11","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1535-7163.MCT-16-0393","volume":"15","author":"LJ Thomas","year":"2016","unstructured":"Thomas LJ, Vitale L, O\u2019Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC, Keler T (2016) Development of a novel antibody\u2013drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1. Mol Cancer Ther 15:2946\u20132954. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0393","journal-title":"Mol Cancer Ther"},{"key":"945_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bcp.12988","volume":"82","author":"B Zhao","year":"2016","unstructured":"Zhao B, Chen R, O\u2019Connor OA, Gopal AK, Ramchandren R, Goy A, Matous JV, Fasanmade AA, Manley TJ, Han TH (2016) Brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol 82:696\u2013705. https:\/\/doi.org\/10.1111\/bcp.12988","journal-title":"Br J Clin Pharmacol"},{"key":"945_CR13","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1681\/ASN.2007030325","volume":"18","author":"Z Zhang","year":"2007","unstructured":"Zhang Z, Humphreys BD, Bonventre JV (2007) Shedding of the urinary biomarker kidney injury Molecule-1 (KIM-1) is regulated by MAP kinases and Juxtamembrane region. J Am Soc Nephrol 18:2704\u20132714. https:\/\/doi.org\/10.1681\/ASN.2007030325","journal-title":"J Am Soc Nephrol"},{"key":"945_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3892\/mmr.2017.6103","volume":"15","author":"Y Jin","year":"2017","unstructured":"Jin Y, Shao X, Sun B, Miao C, Li Z, Shi Y (2017) Urinary kidney injury molecule-1 as an early diagnostic biomarker of obstructive acute kidney injury and development of a rapid detection method. Mol Med Rep 15:1229\u20131235. https:\/\/doi.org\/10.3892\/mmr.2017.6103","journal-title":"Mol Med Rep"},{"key":"945_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jcp.25181","volume":"231","author":"X Zhao","year":"2016","unstructured":"Zhao X, Jiang C, Olufade R, Liu D, Emmett N (2016) Kidney injury Molecule-1 enhances endocytosis of Albumin in renal proximal tubular cells: KIM-1 expression and tubular albumin handling. J Cell Physiol 231:896\u2013907. https:\/\/doi.org\/10.1002\/jcp.25181","journal-title":"J Cell Physiol"},{"key":"945_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11010-016-2700-7","volume":"416","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Cai CX (2016) Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair via ERK MAPK signaling pathway. Mol Cell Biochem 416:109\u2013116. https:\/\/doi.org\/10.1007\/s11010-016-2700-7","journal-title":"Mol Cell Biochem"},{"key":"945_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra0902927","volume":"363","author":"BJ Nankivell","year":"2010","unstructured":"Nankivell BJ, Alexander SI (2010) Rejection of the kidney allograft. N Engl J Med 363:1451\u20131462. https:\/\/doi.org\/10.1056\/NEJMra0902927","journal-title":"N Engl J Med"},{"key":"945_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1172\/JCI32451","volume":"118","author":"T Ueno","year":"2008","unstructured":"Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, Popoola J, Wang Y, Yagita H, Akiba H, Ansari MJ, Yang J, Turka LA, Rothstein DM, Padera RF, Najafian N, Sayegh MH (2008) The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118:742\u2013751. https:\/\/doi.org\/10.1172\/JCI32451","journal-title":"J Clin Invest"},{"key":"945_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","volume":"57","author":"WD Hedrich","year":"2018","unstructured":"Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018) Antibody\u2013drug conjugates: pharmacokinetic\/Pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet 57:687\u2013703. https:\/\/doi.org\/10.1007\/s40262-017-0619-0","journal-title":"Clin Pharmacokinet"},{"key":"945_CR20","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.4049\/jimmunol.180.10.6518","volume":"180","author":"AJ de Souza","year":"2008","unstructured":"de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP (2008) T cell Ig and Mucin Domain-1-mediated T cell activation requires recruitment and activation of Phosphoinositide 3-kinase. J Immunol 180:6518\u20136526. https:\/\/doi.org\/10.4049\/jimmunol.180.10.6518","journal-title":"J Immunol"},{"key":"945_CR21","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4505","volume":"37","author":"DP Petrylak","year":"2019","unstructured":"Petrylak DP, Balar AV, O\u2019Donnell PH, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli J, Melhem-Bertrandt A, Rosenberg JE (2019) EV-201: results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. J Clin Oncol 37:4505\u20134505. https:\/\/doi.org\/10.1200\/JCO.2019.37.18_suppl.LBA4505","journal-title":"J Clin Oncol"},{"key":"945_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2019.37.7_suppl.354","volume":"37","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Faltas BM, Lam ET, Saylor PJ, Bardia A, Hajdenberg J, Morgans AK, Lim EA, Kalinsky K, Simpson PS, Galsky MD, Goswam T, Wegener WA, Petrylak DP (2019) Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I\/II study. J Clin Oncol 37:354\u2013354. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.354","journal-title":"J Clin Oncol"},{"key":"945_CR23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs 32:1246\u20131257. https:\/\/doi.org\/10.1007\/s10637-014-0151-0","journal-title":"Investig New Drugs"},{"key":"945_CR24","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","volume":"24","author":"JA Thompson","year":"2018","unstructured":"Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Do\u00f1ate F, Kollmannsberger CK (2018) Phase I trials of anti-ENPP3 antibody\u2013drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res 24:4399\u20134406. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0481","journal-title":"Clin Cancer Res"},{"key":"945_CR25","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin, and Cisplatin in advanced or metastatic bladder Cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068","journal-title":"J Clin Oncol"},{"key":"945_CR26","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1200\/JCO.2018.79.2531","volume":"36","author":"L Albiges","year":"2018","unstructured":"Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK (2018) Non\u2013clear cell renal cell carcinomas: from shadow to light. J Clin Oncol 36:3624\u20133631. https:\/\/doi.org\/10.1200\/JCO.2018.79.2531","journal-title":"J Clin Oncol"},{"key":"945_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12032-011-9829-8","volume":"29","author":"NB Haas","year":"2012","unstructured":"Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29:761\u2013767. https:\/\/doi.org\/10.1007\/s12032-011-9829-8","journal-title":"Med Oncol"},{"key":"945_CR28","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1002\/cncr.29503","volume":"121","author":"MD Michaelson","year":"2015","unstructured":"Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK (2015) Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma: Sunitinib and gemcitabine in RCC. Cancer 121:3435\u20133443. https:\/\/doi.org\/10.1002\/cncr.29503","journal-title":"Cancer"},{"key":"945_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1","journal-title":"Nat Rev Drug Discov"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00945-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:50:03Z","timestamp":1678510203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00945-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BAM: discloses payment for consulting with Bayer, Astellas, Astra Zeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech and EMD Serono. He received research support to Dana Farber Cancer Institute (DFCI) from Bristol Myers Squibb, Calithera, Exelixis, Seattle Genetics.RF: no competing interests.MG reports other from Medimmune, other from Merck, other from BMS, other from Amgen, other from Tesaro, other from Beigene, other from ABBVIE, other from Aeglea, personal fees and other from Agenus, other from Arcus, other from Astex, other from BluePrint, other from Calithera, other from CellDex, other from Corcept, other from Clovis, other from Eli Lilly, other from Endocyte, other from Five Prime, other from Genocea, other from Neon, other from Plexxicon, personal fees and other from Imaging Endpoints, other from Revolution Medicine, other from Seattle Genetics, other from Serono, other from SynDevRx, other from Toleron, personal fees and other from Tracon, personal fees and other from Deciphera, personal fees and other from Salarius, outside the submitted work.NA discloses payment for consultancy to Astellas, Astra Zeneca, BMS, Bayer, Clovis, Eisai, Exelixis, EMD Serono, Ely Lilly, Foundation Medicine, Genentech, Janssen, Merck, Novartis, Nektar, Pfizer, Pharmacyclics.SG reports grants and personal fees from Bayer, grants and personal fees from BMS, grants from Novartis, personal fees from Exelixis, personal fees from Janssen, grants and personal fees from Corvus, personal fees from Genentech, personal fees from Sanofi\/ Genzyme, grants and personal fees from Pfizer, grants from Acceleron, grants from Merck, grants from Agensys, grants from Eisai, personal fees from EMD Serono, outside the submitted work.DIQ discloses payment for consulting with Bayer, BMS, Exelixis, Merck, Novartis and Pfizer.MR, TH and TK own stock and are employees of Celldex Therapeutics, Inc.TKC discloses payment for consulting to Analysis Group, AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, Bristol-Myers Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Lilly, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology. He received research support to DFCI from Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi\/Aventis, Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}